March 29, 2019
NEW YORK (Reuters) – Proxy advisory firm Institutional Shareholder Services on Friday recommended shareholders of drugmaker Bristol-Myers Squibb Co shareholders vote in favor of its proposed $74 billion takeover of rival Celgene Corp.
“The proposed transaction has sound strategic rationale and the valuation appears reasonable,” ISS said in its report.
Bristol-Myers’ second largest shareholder, Wellington Management, and activist investor Starboard Value LP have opposed the deal, calling it “poorly conceived and ill-advised.”
(Reporting by Svea Herbst, writing by Michael Erman; Editing by Chizu Nomiyama)